United Kingdom (UK)
Recombinant monoclonal antibody to Fel d 1. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma REGN1909.
UniProt Accession Number of Target Protein: P30440
Alternative Name(s) of Target: Major cat allergen; CH2; AG4; Major allergen I polypeptide chain 2; Allergen Cat-1; Allergen Fel d I-B; Allergen FdI; Fel dI; Fel d 1-B
Immunogen: The original antibody was generated by immunizing a Regeneron’s VelocImmune human antibody producing transgenic mouse with recombinant dimeric Fel d 1.
Specificity: This antibody binds chain 2 of the Fel d 1, major cat allergen.
Application Notes: The original human IgG4 antibody was found to block binding of wild type Fel d 1 binding to IgE with a maximum blockade of 51% in a blocking ELISA. Surface plasmon resonance was used to identify the affinity of the antibody towards recombinant and wild type Fel d 1. Crystal structure of the Fab fragment antibody was studied using X-ray crystallography. This antibody in combination with REGN1908 was found to be promising in treatment of cat allergies. A single SC dose of REGN1908–1909 in patients with cat allergy resulted in rapid and clinically meaningful reduction in total nasal symptoms by blocking the early allergic response to nasal challenge with cat allergen (PMID: 29650949).
Antibody first published in:
Orengo et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018; 9: 1421. PMID:29650949
Note on publication:
Describes the generation of two antibodies against major cat allergen Fel d 1 and their possible use in treating cat allergies using allergen-specific immunotherapy (SIT).